Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: analysis of JUPITER trial: Source: Lancet
In view of data suggesting that statins may increase the risk of diabetes, the balance of benefit and risk of their use in primary prevention has become controversial. An analysis of participants from the JUPITER trial was therefore undertaken to address the balance of vascular benefits and diabetes hazard of statin use.
The JUPITER trial involved 17,603 men and women without previous cardiovascular disease or diabetes who were randomised to rosuvastatin 20 mg or placebo and followed up for up to 5 years for the primary endpoint (myocardial infarction, stroke, admission to hospital for unstable angina, arterial revascularisation, or cardiovascular death) and the protocol-pre-specified secondary endpoints of venous thromboembolism, all-cause mortality, and incident physician-reported diabetes. In this analysis, patients were stratified on the basis of having none or at least one of four major risk factors for developing diabetes: metabolic syndrome, impaired fasting ... NeLM News
No comments:
Post a Comment